The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.10
Bid: 29.10
Ask: 30.70
Change: -1.20 (-3.96%)
Spread: 1.60 (5.498%)
Open: 30.00
High: 30.00
Low: 29.10
Prev. Close: 30.30
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Enzyme fermentation capacity expansion progress

20 Jun 2023 07:00

RNS Number : 2099D
EKF Diagnostics Holdings PLC
20 June 2023
 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Enzyme fermentation capacity expansion progress

 

Factory Acceptance Testing on largest 14,500L fermenter completed and on track for delivery this month

Validation process on other fermenters remains on track for operational activity from summer 2023

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that its Life Sciences division's new 14,500L enzyme fermenter has successfully completed Factory Acceptance Testing. This will be the Company's largest fermenter in its capacity expansion programme, and is scheduled for delivery this month, with installation and validation to be completed in Q3 2023.

 

In addition, and as planned, the validation process has begun for the new 65L, 300L, 1,500L, and 3,000L fermenters, which are now all on site in the Life Sciences facility in South Bend, Indiana. This range of smaller fermenters, remain on track to be operational and revenue generating over the summer.

 

Julian Baines, Executive Chair, commented: "Following the successful ISO 13485:2016 and 9001:2015 audits across both of our Life Science sites last month, we're delighted that we continue to make good progress on our capacity expansion plans. We remain on track to have all of our new fermentation capacity in South Bend installed and validated towards the end of Q3 2023, with all but the largest fermenter becoming operational over the summer."

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair / Marc Davies, CFO

 Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas / Oliver Platts

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

· Point-of-Care analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges

 

· Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMZGMVVLGGFZM
Date   Source Headline
25th Aug 20151:10 pmRNSHolding(s) in Company
25th Aug 201511:54 amPRNForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 201511:30 amBUSForm 8.3 - EKF Diagnostics Holdings Plc
25th Aug 201510:52 amRNSHolding(s) in Company
24th Aug 201511:19 amRNSForm 8.3 - EKF Diagnostics Holdings Plc
24th Aug 20157:01 amRNSAnnouncement under rule 2.4 of the Takeover Code
24th Aug 20157:00 amRNSFurther non-binding proposal
18th Aug 201512:00 pmRNSConclusion of Strategic Review
18th Aug 201511:55 amRNSTrading update
10th Aug 20159:25 amRNSHolding(s) in Company
19th May 20152:26 pmRNSResult of AGM
13th May 20157:00 amRNSLaunch of PrecisionPath Colon
1st May 20153:15 pmRNSPosting of Annual Report & Notice of AGM
24th Apr 20154:44 pmRNSHolding(s) in Company
21st Apr 20151:17 pmRNSData for PointMan Technology presented at AACR
8th Apr 201511:41 amRNSHolding(s) in Company
8th Apr 201511:36 amRNSHolding(s) in Company
2nd Apr 20157:00 amRNSShareholder update
26th Mar 20153:47 pmRNSHolding(s) in Company
25th Mar 20153:05 pmRNSHolding(s) in Company
19th Mar 20159:40 amRNSHolding(s) in Company
18th Mar 20153:41 pmRNSHolding(s) in Company
16th Mar 20157:00 amRNSFinal Results
2nd Mar 20157:00 amRNSCollaboration to improve colon cancer treatment
23rd Feb 20157:00 amRNSNotice of results & investor results presentation
2nd Feb 20157:00 amRNSChange of Adviser
28th Jan 20157:00 amRNSTrading update
23rd Jan 20157:00 amRNSCorporate Collaboration
23rd Jan 20157:00 amRNSPointMan collaboration with ANGLE plc
5th Jan 20157:00 amRNSPayment of DiaSpect's deferred consideration
17th Dec 20147:00 amRNSTrading update & potential Board appointment
11th Nov 20144:46 pmRNSHolding(s) in Company
1st Oct 201411:36 amRNSDirector/PDMR Shareholding
23rd Sep 20147:00 amRNSUS collaboration to develop blood tests for cancer
15th Sep 20147:00 amRNSHalf Yearly Report
15th Aug 20147:00 amRNSDirectorate Change
13th Aug 20147:00 amRNSNotice of results and investor briefing
23rd Jul 20147:00 amRNSTrading update
8th Jul 20147:00 amRNSContract Win and Regulatory Approval
13th Jun 201412:53 pmRNSHolding(s) in Company
9th Jun 20145:59 pmRNSGrant of Share Options
6th Jun 20142:46 pmRNSHolding(s) in Company
2nd Jun 20144:15 pmRNSHolding(s) in Company
2nd Jun 20147:00 amRNSMajor step towards detecting cancer in blood
2nd Jun 20147:00 amRNSDirectorate Change
27th May 20143:59 pmRNSHolding(s) in Company
23rd May 201411:30 amRNSHolding(s) in Company
21st May 20144:40 pmRNSSecond Price Monitoring Extn
21st May 20144:35 pmRNSPrice Monitoring Extension
20th May 20144:36 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.